| Symbol | IVVD |
|---|---|
| Name | INVIVYD, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1601 TRAPELO ROAD,SUITE 178, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 781 819-0080 |
| Fax | — |
| — | |
| Website | https://www.invivyd.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001832038 |
| Description | Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The companys lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Invivyd, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352642 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - Invivyd, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000921895-26-002171 <b>Size:</b> 25 KB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06004128 | Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD2… | — | COVID-19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07655180 | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 V… | Phase3 | COVID-19 | Recruiting | 2026-06-08 | 2026-08-01 | ClinicalTrials.gov |
| NCT07298434 | Study of VYD2311 for the Prevention of COVID-19 | Phase3 | COVID-19 | Active_Not_Recruiting | 2026-01-08 | 2026-08-01 | ClinicalTrials.gov |
| NCT06523153 | A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Partici… | Phase1 | COVID-19 | Active_Not_Recruiting | 2024-08-28 | 2025-05-01 | ClinicalTrials.gov |
| NCT06039449 | A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Imm… | Phase3 | COVID-19 | Completed | 2023-09-08 | 2024-11-19 | ClinicalTrials.gov |
| NCT05791318 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Mo… | Phase1 | COVID-19 | Completed | 2023-03-28 | 2024-05-08 | ClinicalTrials.gov |
| NCT04805671 | Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19 | Phase2 | COVID-19 | Terminated | 2021-07-26 | 2022-11-03 | ClinicalTrials.gov |
| NCT04859517 | Evaluation of ADG20 for the Prevention of COVID-19 | Phase2 | COVID-19 | Terminated | 2021-04-27 | 2022-11-04 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo (Normal Saline) | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07655180 |
| VYD2311 | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07655180 |
| COVID-19 mRNA vaccine | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07655180 |
| Placebo | Other | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Placebo | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | RECRUITING | NCT07298434 |
| Normal saline | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04805671 |
| ADG20 | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04805671 |
| Placebo | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05791318 |
| VYD222 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05791318 |
| VYD222 | Other | Preclinical | COVID-19 | NO_LONGER_AVAILABLE | NCT06004128 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04859517 |
| ADG20 | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04859517 |
| Placebo | Other | Phase PHASE1 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT06523153 |
| VYD2311 | Other | Phase PHASE1 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT06523153 |
| Normal saline | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06039449 |
| VYD222 (pemivibart) | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06039449 |
| Placebo | Other | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| VYD2311-MD | Other | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| VYD2311-SD | Other | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| VYD2311-MD | DRUG | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| VYD2311-SD | DRUG | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| VYD2311 | BIOLOGICAL | Phase PHASE1 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT06523153 |
| VYD222 (pemivibart) | DRUG | Phase PHASE3 | COVID-19 | COMPLETED | NCT06039449 |
| VYD222 | DRUG | Preclinical | COVID-19 | NO_LONGER_AVAILABLE | NCT06004128 |
| Placebo | DRUG | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07298434 |
| Normal saline | DRUG | Phase PHASE3 | COVID-19 | COMPLETED | NCT06039449 |
| ADG20 | DRUG | Phase PHASE2 | COVID-19 | TERMINATED | NCT04859517 |